on innovation and access to medicines
Monoclonal antibodies (mAbs) for the treatment and prevention of diseases: why and how to expand global access
A one-stop source providing open access information, research and analysis on policies relating to pharmaceutical innovation and access. Topics are organized under three interrelated themes: Pricing, Intellectual Property and Innovation. Resources include: research syntheses on a range of topics, data sources, webinars and a list of research gaps.
The Knowledge Portal aims to make existing knowledge more available and accessible to communities of policy & practice as a tool to achieve needs-driven innovation and globally-equitable access to medicines.
The research syntheses aim to provide concise, comprehensive overviews of the current state of research on a specific topic. Topics may be listed under more than one theme.
**Disclaimer: The research syntheses aim to provide a concise, comprehensive overview of the current state of research on a specific topic. They seek to cover the main studies in the academic and grey literature, but are not systematic reviews capturing all published studies on a topic. As with any research synthesis, they also reflect the judgments of the researchers. The length and detail vary by topic. Each synthesis will undergo open peer review, and be updated periodically based on feedback received on important missing studies and/or new research. Selected topics focus on national and international-level policies, while recognizing that other determinants of access operate at sub-national level. Work is ongoing on additional topics. We welcome suggestions on the current syntheses and/or on new topics to cover.
All research syntheses are published Open Access, and distributed in accordance with the Creative Commons Attribution Non Commercial International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. Third party material are not included. See: